The tail policy that would have left him personally exposed

The situation

Vartan was reading an insurance renewal notice at his kitchen table, unrelated to the sale of his multi-site surgical group months earlier, when he noticed a term he did not recognize: a reference to a six-year run-off period for directors and officers, tied to a policy he thought had already been finalized and paid for as part of the closing. He was a specialist physician, not a corporate lawyer, and he had trusted his prior advisors to get this right. The notice made him pull the closing file for the first time since the deal wrapped up.

The group had grown from a single clinic into a network of surgical facilities across the region, with Vartan holding a minority stake alongside a larger group led by Siran, who had built most of the network personally and held the controlling interest. When a buyer, represented by Arben, offered to acquire the network outright, the board and shareholders agreed to sell. Vartan, as a minority holder and a sitting director, had signed off on the transaction along with everyone else, relying on the deal team to handle the insurance mechanics that come with any sale of this size.

Director and officer liability does not end the day a company changes hands. Decisions made while Vartan sat on the board, going back years, could still generate a claim long after the sale closed, from a regulatory complaint to a dispute with a former employee to a claim from a patient's estate over a governance decision rather than a clinical one. The standard protection against this is a run-off, or tail, policy: an extended period of coverage, typically several years, that responds to claims arising from conduct before the sale even though the claim itself surfaces afterward. Who pays for that policy, and how much coverage it buys, is usually negotiated as part of the purchase price.

In this deal, the tail policy and its cost had been negotiated once already, before Vartan's prior advisors closed the file, and the split had been presented to the shareholders as settled. Vartan had not questioned it at the time. It was only the renewal notice, arriving months later, that made him look closely enough to realize the number attached to his own protection did not match what he remembered agreeing to, and that the six-year period referenced in his signed documents did not appear consistently across the paperwork he could find.

What the review found

We were retained to look at the tail arrangement on its own, separate from the broader deal file, because Vartan wanted a plain answer to a plain question: was he covered, for how long, and for what. The review took several weeks and turned up more than one problem, none of which had been visible to Vartan or the other minority shareholders when the original settlement was reached, and none of which the closing documents flagged in language a non-lawyer would have caught on a first read.

The first issue was pricing. The tail policy had been quoted and bound based on the network's claims history from several years earlier, before two additional clinic locations were added and before the group's surgical volume roughly doubled. A larger, busier practice carries a different risk profile, and insurers price run-off coverage accordingly. The policy in place had been sized for a smaller, quieter version of the business than the one that had actually been sold, which meant the coverage limits were lower than the group's real exposure warranted, and the gap between the two was wide enough to matter if a serious claim ever arrived.

The second issue was the cost split itself. The purchase agreement allocated the tail premium between buyer and seller, a common and reasonable practice, but the specific split had been negotiated by Vartan's prior advisors without fully accounting for the fact that the six-year period was the longest, and most expensive, tier the insurer offered. A shorter period would have been cheaper and easier to agree, but it would also have left Vartan and the other individual directors exposed for the final two years of the period during which a claim could still arise from pre-closing conduct, since certain claims of this kind can take years to surface, particularly claims tied to a governance or billing decision rather than a single clinical event.

The third issue was structural. The policy named the corporate entity as the primary insured, with individual directors and officers covered as additional insureds, rather than the reverse. In an ordinary run-off, that structure is workable, but here it meant that if the buyer's new ownership group made changes to the surviving entity, including a further sale or restructuring within the six-year window, the individual directors' coverage could be affected by decisions made entirely outside their control, with no mechanism in the original documents requiring notice to Vartan if that happened. For a minority shareholder who no longer sat on the board and had no visibility into the company's later decisions, that gap was the most serious of the three, since it meant his protection could quietly erode without him ever being told.

What we did

1. Pulled the full insurance file and the underlying claims history the original tail policy was priced against, comparing it line by line to the network's actual size and surgical volume at the time of closing, which confirmed the coverage had been quoted for a materially smaller business than the one Vartan had actually helped sell two clinic locations and a doubled caseload earlier.
2. Wrote to the insurer directly to confirm the policy terms in writing rather than relying on the summary in the closing binder, since two internal documents described the run-off period differently and we needed a single, authoritative version before deciding how urgent the problem actually was. The insurer's letter, not the closing binder, became the baseline every later negotiation was measured against, and it was the first document in the file that actually matched what Vartan remembered agreeing to.
3. Approached Arben's side to reopen the tail arrangement on the basis that the original pricing had not reflected the business actually transferred, framing the conversation around a shared interest in getting the coverage right rather than reopening the whole transaction or reallocating any part of the purchase price. The buyer had its own reason to cooperate, since the same policy also protected the directors it had since appointed, and the framing kept the conversation short and cordial rather than adversarial.
4. Negotiated a top-up endorsement with the existing insurer to bring the coverage limits in line with the network's real size at closing, funded through a modest additional payment split roughly along the same proportions as the original premium allocation, which kept the fix contained to the insurance question alone. An endorsement to the existing policy, rather than a fresh one placed with a new carrier, preserved continuity of coverage and avoided any gap while terms were being renegotiated.
5. Restructured the insured order on the policy so individual directors and officers, including Vartan and Siran, held coverage that could not be diminished by later changes to the corporate entity, closing the gap that had left his protection dependent on decisions made by people he no longer had any say over. This is the more common structure for a run-off meant to protect former directors specifically, and moving to it was the single change that mattered most to Vartan once he understood what the old order had exposed him to.
6. Added a notice requirement to the endorsement obliging the surviving entity to tell former directors before taking any action that could affect the run-off policy, so Vartan would learn of a risk to his coverage directly rather than by chance, the way the original gap itself had first surfaced. Without that clause, nothing in the amended policy would have stopped the same kind of silent erosion from happening again under new ownership.
7. Confirmed the corrected six-year period in writing with a clear start and end date tied to the closing, removing the ambiguity between the two internal documents that had first made Vartan suspicious enough to call us. Both dates were cross-checked against the closing date in the purchase agreement itself, so the period could no longer be read two different ways depending on which internal summary someone happened to open.
8. Walked Vartan and Siran through the final coverage in plain terms, including what claims it would and would not respond to and where the boundaries of the six-year period actually fell, so both understood the protection they now held rather than trusting a summary the way the original arrangement had asked them to, and both left with a copy of the endorsement itself rather than a lawyer's paraphrase of it.

The outcome

The corrected run-off policy was in place well within the six-year window it was meant to cover, with limits sized to the business as it actually existed at closing and an insured structure that protected individual directors regardless of what the buyer did with the company afterward. No claim had been made against Vartan, Siran, or any other former director in the time since, and the point of the correction was precisely that none of them would discover a coverage gap only after a claim arrived to test it, when there would be far less room to fix anything.

The cost of fixing the arrangement was real but contained. The top-up endorsement added a modest premium, split between buyer and seller in proportions close to the original agreement, and the legal work to reopen a settled matter added further cost that would not have been necessary had the first advisors gotten the pricing and structure right at closing. Set against a transaction in the fifty-to-eighty-million-dollar range, the correction was a small fraction of the deal's value and did not require reopening the purchase price or any other commercial term the parties had already agreed to and moved past.

What made this a prevention story rather than a near miss was timing. Vartan noticed the renewal notice, asked a question instead of assuming it was fine, and the correction happened before any claim tested the gap it was meant to close. Had a claim arrived first, under the original structure, the outcome could have turned on an insurer's technical reading of a policy that was never sized for the business it was meant to protect, and on whether a change made by the new owners had already touched the coverage without anyone telling him. Instead, the six-year period is now running against coverage that actually matches the risk it was bought to cover, and Vartan reviews his own renewal notices personally rather than assuming someone else already has, a habit Siran adopted as well once the gap was explained to her.

What you can learn from this